Literature DB >> 30717913

Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer.

Fernanda Vaisman1, R Michael Tuttle2.   

Abstract

Thyroid cancer management is rapidly evolving to a personalized management approach. Risk stratification systems are designed to assist in personalized management. Differentiating patients who may benefit from aggressive therapy and intense follow-up as opposed to those who can be successfully treated with minimalized initial management options and follow-up is crucial to the development of the right treatment plan for the right patient in order to optimize initial therapy and follow-up testing. This article aims to describe and discuss the risk stratification systems currently recommended for differentiated thyroid cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mortality; Recurrence; Response to therapy; Risk stratification; Thyroid cancer

Mesh:

Year:  2019        PMID: 30717913     DOI: 10.1016/j.ecl.2018.11.002

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  6 in total

1.  Incomplete response to therapy in intermediate- and high-risk thyroid cancer.

Authors:  Ali S Alzahrani; Noha Mukhtar
Journal:  Endocrine       Date:  2022-09-08       Impact factor: 3.925

Review 2.  Updates on the Management of Thyroid Cancer.

Authors:  Katherine A Araque; Sriram Gubbi; Joanna Klubo-Gwiezdzinska
Journal:  Horm Metab Res       Date:  2020-02-10       Impact factor: 2.936

Review 3.  Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis.

Authors:  Likun Cui; Dongdong Feng; Chaofan Zhu; Qiuyu Li; Wenqing Li; Baoguo Liu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-06-21

4.  KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment.

Authors:  Yue Han; Jing Chen; Dianjun Wei; Baoxi Wang
Journal:  Comput Math Methods Med       Date:  2022-08-16       Impact factor: 2.809

5.  Natural Course of the American Thyroid Association Response to Therapy Statuses (Dynamic Risk Stratification) in Differentiated Thyroid Cancer.

Authors:  Noha Mukhtar; Hadeel Aljamei; Abeer Aljomaiah; Yosra Moria; Ali S Alzahrani
Journal:  Eur Thyroid J       Date:  2020-12-01

6.  Course and Predictive Factors of Incomplete Response to Therapy in Low- and Intermediate-Risk Thyroid Cancer.

Authors:  Ali S Alzahrani; Yosra Moria; Noha Mukhtar; Hadeel Aljamei; Sedra Mazi; Lina Albalawi; Abeer Aljomaiah
Journal:  J Endocr Soc       Date:  2020-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.